Hypogonadism Clinical Trials 2023

What are the top hospitals conducting hypogonadism research?

When it comes to advancing our understanding and treatment of hypogonadism, several top hospitals are leading the way with their clinical trial efforts. Massachusetts General Hospital in Boston stands out as a pioneer in this field, currently conducting eight active trials focused on hypogonadism, with a cumulative total of 26 trials since embarking on their first investigation back in 1989. Also situated in Boston is Brigham and Women's Hospital, which may have fewer ongoing trials at three but has made significant contributions through four past hypogonadism studies since initiating its first trial in 2006.

Heading west to Seattle, the Veterans Affairs Puget Sound Health Care System may have only two active hypogonadism trials to date but should not be underestimated. Their commitment to research is evident as they commenced their initial trial for this condition as recently as 2021. Similarly new to the scene is Atlanta's Emory University Hospital/Winship Cancer Institute, where one active hypogonadism trial showcases the institution's dedication to investigating novel approaches for managing this hormonal disorder.

Finally, making valuable strides from Gainesville is the North Florida/South Georgia Veterans Health System. Though they currently have one active hypogonadism trial underway and have conducted just two previous investigations into this condition since recording their inaugural study in 2007, every contribution counts towards expanding knowledge and improving patient outcomes.

These hospitals collectively demonstrate that progress takes time and dedication when exploring complex conditions like hypogonadism. Through innovative clinical trials conducted across multiple locations nationwide we inch closer towards more effective treatments which hold promise for those affected by hormone imbalances alike

Which are the best cities for hypogonadism clinical trials?

When it comes to hypogonadism clinical trials, several cities in the United States are at the forefront of research and investigation. Boston, Massachusetts leads with 11 active trials exploring treatments such as GnRH, Testosterone Undecanoate, and kisspeptin. Gainesville, Florida; Seattle, Washington; Houston and San Antonio in Texas also have ongoing studies investigating various interventions like locomotor training and different forms of testosterone therapy. These cities offer individuals living with hypogonadism access to cutting-edge clinical trials that aim to improve treatment options and quality of life for patients.

Which are the top treatments for hypogonadism being explored in clinical trials?

Hypogonadism, a condition characterized by low testosterone levels, is the focus of ongoing clinical trials exploring various treatment options. Among the top contenders are:

• GnRH: Currently being investigated in three active trials and having a total of 12 hypogonadism-related trials since its introduction in 1989.

• Testosterone Cypionate: Under evaluation in one active trial with two all-time hypogonadism studies recorded since 2011.

• Locomotor Training: A newcomer to the scene, this treatment method is currently being tested in one active trial for hypogonadism research after its first listing just this year (2021).

• Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]: Also introduced this year (2021), it has entered one active clinical trial among other reported studies focusing on treating hypogonadism.

• Testosterone gel 1.62%: Having been listed back in 2009, it remains an area of interest with one ongoing trial and two all-time hypogonadism trials dedicated to studying its effectiveness.

These treatments represent promising avenues that hold potential for improving outcomes for individuals affected by hypogonadism.

What are the most recent clinical trials for hypogonadism?

Exciting advancements are being made in the realm of hypogonadism treatment, as recent clinical trials offer promising options for patients. Among these trials is the kisspeptin pump, which has shown potential in restoring hormone levels and addressing symptoms associated with hypogonadism. Additionally, NatestoTM and Jatenzo Pill have displayed positive outcomes in their respective phases, providing alternative therapeutic approaches for individuals with this condition. Another notable study focused on testosterone supplementation has also yielded encouraging results. With these innovative interventions at hand, those affected by hypogonadism can look forward to improved management strategies and a better quality of life ahead.

What hypogonadism clinical trials were recently completed?

Two recent clinical trials have shed light on potential advancements in the treatment of hypogonadism. In July 2021, Acerus Pharmaceuticals Corporation completed a trial investigating the effectiveness of Natesto in managing this condition. Furthermore, Massachusetts General Hospital concluded a trial on GnRH therapy back in September 2011. These studies serve as valuable contributions to our understanding and management of hypogonadism, offering hope for individuals affected by this condition.